Clinical Trial Update: CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation [NA]

View source ↗

Summary

A CRISPR/Cas9 instantaneous gene editing therapy for MYOC-mutant primary open-angle glaucoma is in a clinical trial and currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Open-angle Glaucoma

Drugs mentioned

• CRISPR/Cas9 instantaneous gene editing therapy

Snippet

Sponsor: Shanghai BDgene Co., Ltd. | Conditions: Primary Open Angle Glaucoma | NA | Status: RECRUITING